In conclusion, the actress in the Entyvio commercial is the talented Lorraine Toussaint. With her exceptional acting skills and ability to bring characters to life, Toussaint has captivated audiences in various films, television shows, and stage productions.

How quickly does Entyvio work? In studies of Entyvio, most people had fewer symptoms of ulcerative colitis or Crohn's disease after 6 weeks of treatment.

Entyvio has an average rating of 5.8 out of 10 from a total of 135 reviews on Drugs.com. 44% of reviewers reported a positive experience, while 32% reported a negative experience.

Entyvio is meant to be used as a long-term treatment. If you and your doctor determine that Entyvio is safe and effective for you, you'll likely take it long term. If Entyvio doesn't reduce your CD or UC symptoms after 14 weeks of treatment, your doctor may have you stop taking the drug.

Entyvio, from Takeda Pharmaceuticals, was first approved by the U.S. Food and Drug Administration (FDA) on May 20, 2014.

Women are more likely to develop Crohn's disease than men, but more men develop ulcerative colitis than women. Even though the average age of developing IBD is between 15 and 35, more men are diagnosed with ulcerative colitis in their 50s and 60s than women of the same age.

At Week 52, in the anti‑TNFα naïve subpopulation, clinical remission rates were 52% for those who received Entyvio vs. 27% for those who received placebo. In the anti‑TNFα failure subpopulation, clinical remission rates were 28% for those who received Entyvio vs. 13% for those who received placebo.

Signs Your Ulcerative Colitis Treatment Isn't Working Dr. Philpott says that an increase in your bowel movements, trouble or pain passing stool, weight loss, fevers, blood in stool, and fatigue could be signs that it's time to discuss a change with your doctor.

People who take Entyvio have an increased risk of infection, such as the common cold or flu. More serious infections may also occur. These might include tuberculosis or an infection in the brain called progressive multifocal leukoencephalopathy (see below).

ENTYVIO made remission real for many people with moderate to severe ulcerative colitis (UC) In two clinical trials, ENTYVIO delivered results for adults with moderate to severe ulcerative colitis when other medicines had not worked well enough or could not be tolerated.

Entyvio is a biologic drug, which means that it's made from living cells. If this medication works for you, your doctor will likely recommend that you use it long term.

Kynteles which is sold globally as Entyvio in more than 60 countries, generated sales of $3.2 billion in FY20. Takeda India, part of the Japanese pharma major Takeda Pharmaceutical Company announced the launch of its blockbuster biologic drug Vedolizumab in India as part of its Gastrointestinal (GI) portfolio.